New hope for tough cancers: testing a Triple-Threat treatment
NCT ID NCT07506057
Summary
This study is testing a combination of three drugs—trastuzumab, serplulimab, and chemotherapy—for people with advanced HER2-positive biliary tract cancer or bladder cancer that has spread and no longer responds to standard treatments. The goal is to see if this three-drug approach can shrink tumors and extend life for these patients. The study will measure how many people respond to treatment, how long they live, and how safe the combination is.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of China Medical University
RECRUITINGShenyang, Liaoning, 110001, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.